FIGURE 6.

Predicted concentration versus time profiles following QM (A) and Q2M (B) regimens. The final injection is administered at (A) 12 or (B) 11 months after the initiation injection. Residual variability was not included in the simulation. Negative time on x axis (−1) indicates that oral dosing starts approximately 1 month prior to the initiation injection. IM, intramuscular; LA, long‐acting; PA‐IC90, in vitro protein‐adjusted concentration resulting in 90% of the maximum inhibition of viral growth for CAB (0.166 μg/mL); PO, oral; QM, once every month; Q2M, once every 2 months; QD, once daily